Celcuity Inc.

Contributing Author

Recent Articles by Celcuity Inc.

Jul-30	Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants CELC GlobeNewswire
Jul-28	Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock CELC GlobeNewswire
Jul-28	Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival ("PFS") Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial CELC GlobeNewswire
Jul-25	Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer CELC GlobeNewswire
Jul-24	Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer CELC GlobeNewswire
Jul-14	Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042 CELC GlobeNewswire
Jun-30	Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib CELC GlobeNewswire
May-21	Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences CELC GlobeNewswire
May-14	Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update CELC GlobeNewswire
May-07	Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call CELC GlobeNewswire